Literature DB >> 29164988

Development of Peritoneal Carcinomatosis in Epithelial Ovarian Cancer: A Review.

Juliette O A M van Baal1, Cornelis J F van Noorden2, Rienk Nieuwland3, Koen K Van de Vijver4, Auguste Sturk5, Willemien J van Driel1, Gemma G Kenter1, Christianne A R Lok1.   

Abstract

Epithelial ovarian cancer (EOC) metastasizes intra-abdominally with often numerous, superficial, small-sized lesions. This so-called peritoneal carcinomatosis is difficult to treat, and peritoneal recurrences are frequently observed, leading to a poor prognosis. Underlying mechanisms of interactions between EOC and peritoneal cells are incompletely understood. This review summarizes and discusses the development of peritoneal carcinomatosis from a cell-biological perspective, focusing on characteristics of EOC and peritoneal cells. We aim to provide insight into how peritoneum facilitates tumor adhesion but limits size of lesions and depth of invasion. The development of peritoneal carcinomatosis is a multistep process that requires adaptations of EOC and peritoneal cells. Mechanisms that enable tumor adhesion and growth involve cadherin restructuring on EOC cells, integrin-mediated adhesion, and mesothelial evasion by mechanical forces driven by integrin-ligand interactions. Clinical trials targeting these mechanisms, however, showed only limited effects. Other factors that inhibit tumor growth and deep invasion are virtually unknown. Future studies are needed to elucidate the exact mechanisms that underlie the development and limited growth of peritoneal carcinomatosis. This review on development of peritoneal carcinomatosis of EOC summarizes the current knowledge and its limitations. Clarification of the stepwise process may inspire future research to investigate new treatment approaches of peritoneal carcinomatosis.

Entities:  

Keywords:  epithelial ovarian carcinoma; pathogenesis; peritoneal barrier; peritoneal metastases; peritoneal metastasis; peritoneum

Mesh:

Year:  2017        PMID: 29164988      PMCID: PMC5794203          DOI: 10.1369/0022155417742897

Source DB:  PubMed          Journal:  J Histochem Cytochem        ISSN: 0022-1554            Impact factor:   2.479


  99 in total

Review 1.  Extracellular matrix determinants of proteolytic and non-proteolytic cell migration.

Authors:  Katarina Wolf; Peter Friedl
Journal:  Trends Cell Biol       Date:  2011-10-27       Impact factor: 20.808

2.  Exosomes in the ascites of ovarian cancer patients: origin and effects on anti-tumor immunity.

Authors:  Peng Peng; You Yan; Shen Keng
Journal:  Oncol Rep       Date:  2010-12-22       Impact factor: 3.906

Review 3.  Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer.

Authors:  Kenneth Jaaback; Nick Johnson; Theresa A Lawrie
Journal:  Cochrane Database Syst Rev       Date:  2016-01-12

4.  Role of integrin receptors for fibronectin, collagen and laminin in the regulation of ovarian carcinoma functions in response to a matrix microenvironment.

Authors:  Nuzhat Ahmed; Clyde Riley; Greg Rice; Michael Quinn
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

5.  Quantitation of tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 in the effusions of ovarian epithelial neoplasms.

Authors:  W H Kutteh; C C Kutteh
Journal:  Am J Obstet Gynecol       Date:  1992-12       Impact factor: 8.661

6.  First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors.

Authors:  Debashis Sarker; Joo Ern Ang; Richard Baird; Rebecca Kristeleit; Krunal Shah; Victor Moreno; Paul A Clarke; Florence I Raynaud; Gallia Levy; Joseph A Ware; Kathryn Mazina; Ray Lin; Jenny Wu; Jill Fredrickson; Jill M Spoerke; Mark R Lackner; Yibing Yan; Lori S Friedman; Stan B Kaye; Mika K Derynck; Paul Workman; Johann S de Bono
Journal:  Clin Cancer Res       Date:  2014-11-04       Impact factor: 12.531

7.  Chemokine axes CXCL12/CXCR4 and CXCL16/CXCR6 correlate with lymph node metastasis in epithelial ovarian carcinoma.

Authors:  Li Guo; Zhu-Mei Cui; Jia Zhang; Yu Huang
Journal:  Chin J Cancer       Date:  2011-05

8.  Pretreatment with VEGF(R)-inhibitors reduces interstitial fluid pressure, increases intraperitoneal chemotherapy drug penetration, and impedes tumor growth in a mouse colorectal carcinomatosis model.

Authors:  Félix Gremonprez; Benedicte Descamps; Andrei Izmer; Christian Vanhove; Frank Vanhaecke; Olivier De Wever; Wim Ceelen
Journal:  Oncotarget       Date:  2015-10-06

9.  Ovarian tumor attachment, invasion, and vascularization reflect unique microenvironments in the peritoneum: insights from xenograft and mathematical models.

Authors:  Mara P Steinkamp; Kimberly Kanigel Winner; Suzy Davies; Carolyn Muller; Yong Zhang; Robert M Hoffman; Abbas Shirinifard; Melanie Moses; Yi Jiang; Bridget S Wilson
Journal:  Front Oncol       Date:  2013-05-17       Impact factor: 6.244

Review 10.  Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research.

Authors:  Nuzhat Ahmed; Kaye L Stenvers
Journal:  Front Oncol       Date:  2013-09-25       Impact factor: 6.244

View more
  23 in total

1.  Host CYP27A1 expression is essential for ovarian cancer progression.

Authors:  Sisi He; Liqian Ma; Amy E Baek; Anna Vardanyan; Varsha Vembar; Joy J Chen; Adam T Nelson; Joanna E Burdette; Erik R Nelson
Journal:  Endocr Relat Cancer       Date:  2019-07       Impact factor: 5.678

2.  Apparent Diffusion Coefficient Histogram Analysis for Assessing Tumor Staging and Detection of Lymph Node Metastasis in Epithelial Ovarian Cancer: Correlation with p53 and Ki-67 Expression.

Authors:  Feng Wang; Yuxiang Wang; Yan Zhou; Congrong Liu; Dong Liang; Lizhi Xie; Zhihang Yao; Jianyu Liu
Journal:  Mol Imaging Biol       Date:  2019-08       Impact factor: 3.488

3.  Role of [68Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of peritoneal carcinomatosis and comparison with [18F]-FDG PET/CT.

Authors:  Liang Zhao; Yizhen Pang; Zuoming Luo; Kaili Fu; Tingting Yang; Long Zhao; Long Sun; Hua Wu; Qin Lin; Haojun Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-01-07       Impact factor: 9.236

4.  Tumor Treating Fields for Ovarian Carcinoma: A Modeling Study.

Authors:  Edwin Lok; Pyay San; Victoria White; Olivia Liang; Page C Widick; Sindhu Pisati Reddy; Eric T Wong
Journal:  Adv Radiat Oncol       Date:  2021-05-17

5.  Investigating the mechanisms of peritoneal metastasis in gastric adenocarcinoma using a novel ex vivo peritoneal explant model.

Authors:  Marco Magalhaes; Carol J Swallow; Deanna Ng; Aiman Ali; Kiera Lee; Denise Eymael; Kento Abe; Shelly Luu; Karineh Kazazian; Yi Qing Lu; Savtaj Brar; James Conner
Journal:  Sci Rep       Date:  2022-07-07       Impact factor: 4.996

Review 6.  Spheroid Formation and Peritoneal Metastasis in Ovarian Cancer: The Role of Stromal and Immune Components.

Authors:  Militsa Rakina; Anna Kazakova; Alisa Villert; Larisa Kolomiets; Irina Larionova
Journal:  Int J Mol Sci       Date:  2022-06-01       Impact factor: 6.208

7.  CA125, CEA, CA19-9, and Heteroploid Cells in Ascites Fluid May Help Diagnose Peritoneal Carcinomatosis in Patients with Gastrointestinal and Ovarian Malignancies.

Authors:  Lin Deng; Shikong Guo; Hong Li; Xianghui You; Yang Song; Haichuan Su
Journal:  Cancer Manag Res       Date:  2020-10-22       Impact factor: 3.989

8.  Overall clinical and trichoscopic analysis performed in patients who underwent pressurized intraperitoneal aerosol chemotherapy (PIPAC) treatment for peritoneal carcinomatosis - initial trial preliminary report.

Authors:  Maciej Nowacki; Katarzyna Nowacka; Iwona Głowacka; Barbara Zegarska; Wojciech Zegarski
Journal:  Postepy Dermatol Alergol       Date:  2019-08-30       Impact factor: 1.837

9.  Poor perfusion of the microvasculature in peritoneal metastases of ovarian cancer.

Authors:  Arnoud W Kastelein; Laura M C Vos; Juliette O A M van Baal; Jasper J Koning; Vashendriya V V Hira; Rienk Nieuwland; Willemien J van Driel; Zühre Uz; Thomas M van Gulik; Jacco van Rheenen; Can Ince; Jan-Paul W R Roovers; Cornelis J F van Noorden; Christianne A R Lok
Journal:  Clin Exp Metastasis       Date:  2020-02-01       Impact factor: 5.150

10.  A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.

Authors:  Pia Leandersson; Anna Åkesson; Ingrid Hedenfalk; Susanne Malander; Christer Borgfeldt
Journal:  PLoS One       Date:  2020-10-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.